Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 28
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Hepatic p63 regulates steatosis via IKK beta/ER stress

  • Porteiro, Begona
  • Fondevila, Marcos F.
  • Delgado, Teresa C.
  • Iglesias, Cristina
  • Imbernon, Monica
  • Iruzubieta, Paula
  • Crespo, Javier
  • Zabala-Letona, Amaia
  • Ferno, Johan
  • Gonzalez-Teran, Barbara
  • Matesanz, Nuria
  • Hernandez-Cosido, Lourdes
  • Marcos, Miguel
  • Tovar, Sulay
  • Vidal, Anxo
  • Sanchez-Ceinos, Julia
  • Malagon, Maria M.
  • Pombo, Celia
  • Zalvide, Juan
  • Carracedo, Arkaitz
  • Buque, Xabier
  • Dieguez, Carlos
  • Sabio, Guadalupe
  • Lopez, Miguel
  • Aspichueta, Patricia
  • Martinez-Chantar, Maria L.
  • Nogueiras, Ruben
p53 family members control several metabolic and cellular functions. The p53 ortholog p63 modulates cellular adaptations to stress and has a major role in cell maintenance and proliferation. Here we show that p63 regulates hepatic lipid metabolism. Mice with liver-specific p53 deletion develop steatosis and show increased levels of p63. Down-regulation of p63 attenuates liver steatosis in p53 knockout mice and in diet-induced obese mice, whereas the activation of p63 induces lipid accumulation. Hepatic overexpression of N-terminal transactivation domain TAp63 induces liver steatosis through IKK beta activation and the induction of ER stress, the inhibition of which rescues the liver functions. Expression of TAp63, IKK beta and XBP1s is also increased in livers of obese patients with NAFLD. In cultured human hepatocytes, TAp63 inhibition protects against oleic acid-induced lipid accumulation, whereas TAp63 overexpression promotes lipid storage, an effect reversible by IKK beta silencing. Our findings indicate an unexpected role of the p63/IKK beta/ER stress pathway in lipid metabolism and liver disease.
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

LUZP1 Controls Cell Division, Migration and Invasion Through Regulation of the Actin Cytoskeleton

  • Bozal Basterra, Laura
  • González Santamarta, María
  • Muratore, Veronica
  • Martín Martín, Natalia
  • Ercilla Eguiarte, Amaia
  • Rodríguez Pérez, José Antonio
  • Carracedo Pérez, Arkaitz
  • Sutherland, James D.
  • Barrio Olano, María Rosa
LUZP1 is a centrosomal and actin cytoskeleton-localizing protein that regulates both ciliogenesis and actin filament bundling. As the cytoskeleton and cilia are implicated in metastasis and tumor suppression, we examined roles for LUZP1 in the context of cancer. Here we show that LUZP1 exhibits frequent genomic aberrations in cancer, with a predominance of gene deletions. Furthermore, we demonstrate that CRISPR/Cas9-mediated loss of Luzp1 in mouse fibroblasts promotes cell migration and invasion features, reduces cell viability, and increases cell apoptosis, centriole numbers, and nuclear size while altering the actin cytoskeleton. Loss of Luzp1 also induced changes to ACTR3 (Actin Related Protein 3, also known as ARP3) and phospho-cofilin ratios, suggesting regulatory roles in actin polymerization, beyond its role in filament bundling. Our results point to an unprecedented role for LUZP1 in the regulation of cancer features through the control of actin cytoskeleton., We are grateful to the Fundacion Inocente, Inocente for their support. We also acknowledge funding by the grants BFU2017-84653-P (MINECO/FEDER, EU), SEV-2016-0644 (Severo Ochoa Excellence Program), 765445-EU (UbiCODE Program), SAF2017-90900-REDT (UBIRed Program), and IT1165-19 (Basque Country Government). Additional support was provided by the Department of Industry, Tourism, and Trade of the Basque Country Government (Elkartek Research Programs) and by the Innovation Technology Department of the Bizkaia County. LB-B acknowledges POSTD19048BOZA (Fundacion Cientifica AECC). VM acknowledges PRE2018086230 (MINECO/FEDER, EU). AC acknowledges the Basque Department of education (IKERTALDE IT1106-16), the MCIU [PID2019-108787RB-I00 (FEDER/EU)], the AECC (IDEAS175CARR; GCTRA18006CARR), La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17/and the European Research Council (Starting Grant 336343, PoC 754627, Consolidator grant 819242). CIBERONC was co-funded with FEDER funds. We are also grateful to Maria Vivanco's lab for providing reagents.
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis

  • Palomo Irigoyen, Marta
  • Pérez Andrés, Encarni
  • Iruarrizaga Lejarreta, Marta
  • Barreira Manrique, Adrián
  • Tamayo Caro, Miguel
  • Vila Vecilla, Laura
  • Moreno Cugnon, Leire
  • Beitia, Nagore
  • Medrano, Daniela
  • Fernández Ramos, David
  • Lozano, Juan José
  • Okawa, Satoshi
  • Lavín, José L.
  • Martín Martín, Natalia
  • Sutherland, James D.
  • Gutiérez de Juan, Virginia
  • González López, Monika
  • Macías Cámara, Nuria
  • Mosén Ansorena, David
  • Laraba, Liyam
  • Hanemann, C. Oliver
  • Ercolano, Emanuela
  • Parkinson, David B.
  • Schultz, Christopher W.
  • Araúzo Bravo, Marcos J.
  • Ascensión, Alex M.
  • Gerovska, Daniela
  • Iribar López, Haizea
  • Izeta Permisán, Ander
  • Pytel, Peter
  • Krastel, Philipp
  • Provenzani, Alessandro
  • Seneci, Pierfausto
  • Carrasco, Ruben D.
  • Del Sol, Antonio
  • Martínez Chantar, María Luz
  • Barrio Olano, María Rosa
  • Serra, Eduard
  • Lazaro, Conxi
  • Flanagan, Adrienne M.
  • Gorospe, Myriam
  • Ratner, Nancy
  • Aransay Bañares, Ana María
  • Carracedo Pérez, Arkaitz
  • Varela Rey, Marta
  • Woodhoo, Ashwin
Cancer cells can develop a strong addiction to discrete molecular regulators, which control the aberrant gene expression programs that drive and maintain the cancer phenotype. Here, we report the identification of the RNA-binding protein HuR/ELAVL1 as a central oncogenic driver for malignant peripheral nerve sheath tumors (MPNSTs), which are highly aggressive sarcomas that originate from cells of the Schwann cell lineage. HuR was found to be highly elevated and bound to a multitude of cancer-associated transcripts in human MPNST samples. Accordingly, genetic and pharmacological inhibition of HuR had potent cytostatic and cytotoxic effects on tumor growth, and strongly suppressed metastatic capacity in vivo. Importantly, we linked the profound tumorigenic function of HuR to its ability to simultaneously regulate multiple essential oncogenic pathways in MPNST cells, including the Wnt/beta-catenin, YAP/TAZ, RB/E2F, and BET pathways, which converge on key transcriptional networks. Given the exceptional dependency of MPNST cells on HuR for survival, proliferation, and dissemination, we propose that HuR represents a promising therapeutic target for MPNST treatment., This work was funded by grants to AW from the Spanish Association Against Cancer (AECC; JP Vizcaya); Spanish Ministry of Science, Innovation and Universities (MCIU)/Agencia Estatal de Investigacion (AEI)/European Regional Development Fund (FEDER), European Union (EU) (Subprograma Ramon y Cajal RYC2010-06901; Proyectos Retos Investigacion RTI2018-097503-B-I00, SAF2015-65360-R; Proyectos Explora Ciencia SAF2015-72416-EXP; Proyectos Europa Excelencia SAF2015-62588-ERC); the BBVA Foundation; Basque Department of Industry, Tourism and Trade (Elkartek) and Education (PI2013-46); Fundacion Vasca de Innovacion e Investigacion Sanitarias EiTB Maratoia (BIO13/CI/015); the Neurofibromatosis Therapeutic Acceleration Program; and the European Research Council (consolidator grant under the EU's Horizon 2020 research and innovation programme; grant agreement 865157). MVR is grateful for the support of a 2017 Leonardo Grant for Researchers and Cultural Creators (BBVA Foundation), Accion Estrategica Ciber Emergentes 2018 (Ciberehd-ISCIII), and Gilead Sciences International Research Scholars Program in Liver Disease. The work of AC is supported by the Basque Department of Industry, Tourism and Trade (Elkartek) and Education (IKERTALDE IT1106-16); the BBVA Foundation; the MCIU/AEI (SAF2016-79381-R [FEDER/EU]; Severo Ochoa Excellence Accreditation SEV-2016-0644; Excellence Networks SAF20168-1975-REDT); the European Training Networks Project (H2020-MSCA-ITN-308 2016 721532); the AECC (IDEAS175CARR, GCTRA18006CARR); La Caixa Foundation (HR17-00094); and the European Research Council (Starting Grant 336343, PoC 754627). MG was supported by the Intramural Research Program of the National Institute on Aging, NIH. MPI is grateful for the support of the Basque Government of Education fellowship. MTC is grateful for the support of "Ayudas para contratos predoctorales para la formacion de doctores" (MCIU/AEI/FEDER, EU). COH acknowledges funding from Brain Tumour Research. RB acknowledges MCIU/AEI/FEDER, EU (BFU2014-52282-P and BFU2017-84653-P). ES and CL are supported by the Carlos III National Health Institute funded by FEDER funds - a way to build Europe (CIBERONC) and the Government of Catalonia (2017SGR496). MLM-C acknowledges support from MCIU/AEI/FEDER, EU (SAF2017-87301-R); Asociacion Espanola Contra El Cancer (AECC); AECC Canceres Raros; BBVA Biomedicina (UMBRELLA); and La CAIXA Foundation (LCF/PR/HP17/52190004). AP was supported by Associazione Italiana Ricerca sul Cancro (AIRC; IG 2018 Id.21548). CIBERehd is funded by the Instituto de Salud Carlos III. We thank MCIU for the Severo Ochoa Excellence Accreditation (SEV-2016-0644).
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

Identification of proximal SUMO-dependent interactors using SUMO-ID

  • Barroso Gomila, Orhi
  • Trulsson, Erik
  • Muratore, Veronica
  • Canosa, Iñigo
  • Merino Cacho, Laura
  • Cortázar, Ana Rosa
  • Pérez Fernández, Coralia
  • Azkargorta, Mikel
  • Iloro, Ibon
  • Carracedo Pérez, Arkaitz
  • Aransay Bañares, Ana María
  • Elortza, Felix
  • Mayor Martínez, Ugo
  • Verteegal, Alfred C. O.
  • Barrio Olano, María Rosa
  • Sutherland, James D.
[EN]The fast dynamics and reversibility of posttranslational modifications by the ubiquitin family pose significant challenges for research. Here we present SUMO-ID, a technology that merges proximity biotinylation by TurboID and protein-fragment complementation to find SUMO-dependent interactors of proteins of interest. We develop an optimized split-TurboID version and show SUMO interaction-dependent labelling of proteins proximal to PML and RANGAP1. SUMO-dependent interactors of PML are involved in transcription, DNA damage, stress response and SUMO modification and are highly enriched in SUMO Interacting Motifs, but may only represent a subset of the total PML proximal proteome. Likewise, SUMO-ID also allow us to identify interactors of SUMOylated SALL1, a less characterized SUMO substrate. Furthermore, using TP53 as a substrate, we identify SUMO1, SUMO2 and Ubiquitin preferential interactors. Thus, SUMO-ID is a powerful tool that allows to study the consequences of SUMO-dependent interactions, and may further unravel the complexity of the ubiquitin code., We are thankful to Iraide Escobes for her work in the Proteomics Platform at CIC bioGUNE and Arnoud de Ru in the Center for Proteomics and Metabolomics at the LUMC. O.B.-G., F.T., R.B. and A.C.O.V. acknowledge funding by the grant 765445-EU (UbiCODE Program). R.B. acknowledges funding by grants BFU2017-84653-P and PID2020-114178GB-I00 (MINECO/FEDER, EU), SEV-2016-0644 (Severo Ochoa Excellence Program), SAF2017-90900-REDT (UBIRed Program) and IT1165-19 (Basque Country Government). Additional support was provided by the Department of Industry, Tourism, and Trade of the Basque Country Government (Elkartek Research Programs) and by the Innovation Technology Department of the Bizkaia County. VM acknowledges FPI grant PRE2018-086230 (MINECO/FEDER, EU). F.E. is at Proteomics Platform, member of ProteoRed-ISCIII (PT13/0001/0027). F.E. and A.M.A. acknowledge CIBERehd. A.C. acknowledges the Basque Department of education (IKERTALDE IT1106-16), the MCIU (PID2019-108787RB-I00 (FEDER/EU), Severo Ochoa Excellence Accreditation SEV-2016-0644, Excellence Networks RED2018-102769-T), the AECC (GCTRA18006CARR), La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17, and the European Research Council (Starting Grant 336343, PoC 754627, Consolidator grant 819242). CIBERONC was co-funded with FEDER funds. U.M. acknowledges the Basque Government Department of Education (IT1165-19) and the Spanish MCIU (SAF2016-76898-P (FEDER/EU)).
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer

  • Hermanova, Ivana
  • Zúñiga García, Patricia
  • Caro Maldonado, Alfredo
  • Fernandez Ruiz, Sonia
  • Salvador, Fernando
  • Martín Martín, Natalia
  • Zabala Letona, Amaia
  • Nuñez Olle, Marc
  • Torrano, Verónica
  • Camacho, Laura
  • Lizcano, José Miguel
  • Talamillo, Ana
  • Carreira, Suzanne
  • Gurel, Bora
  • Cortazar, Ana Rosa
  • Guiu, Marc
  • López, Jose I.
  • Martínez Romero, Anabel
  • Astobiza, Ianire
  • Valcarcel Jimenez, Lorea
  • Lorente, Mar
  • Arruabarrena-Aristorena, Amaia
  • Velasco, Guillermo
  • Gomez Muñoz, Antonio
  • Suarez Cabrera, Cristian
  • Lodewijk, Iris
  • Flores, Juana M.
  • Sutherland, James David
  • Barrio, Rosa
  • Bono, Johann Sebastian de
  • Paramio, Jesús M.
  • Trka, Jan
  • Graupera i Garcia-Milà, Mariona
  • Gomis i Cabré, Roger
  • Carracedo, Arkaitz
Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model an aggressive form of prostate cancer and show the unconventional association of LKB1 dosage to prostate tumorigenesis. Whereas loss of Lkbl alone in the murine prostate epithelium was inconsequential for tumorigenesis, its combination with an oncogenic insult, illustrated by Pten heterozygosity, elicited lethal metastatic prostate cancer. Despite the low frequency of LKB1 deletion in patients, this event was significantly enriched in lung metastasis. Modeling the role of LKB1 in cellular systems revealed that the residual activity retained in a reported kinase-dead form, LKB1(K781), was sufficient to hamper tumor aggressiveness and metastatic dissemination. Our data suggest that prostate cells can function normally with low activity of LKB1, whereas its complete absence influences prostate cancer pathogenesis and dissemination.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Low-dose statin treatment increases prostate cancer aggressiveness

  • Caro Maldonado, Alfredo
  • Camacho, Laura
  • Zabala Letona, Amaia
  • Torrano, Verónica
  • Fernández Ruiz, Sonia
  • Zamacola-Bascaran, Kepa
  • Arreal, Leire
  • Valcarcel Jimenez, Lorea
  • Martín-Martín, Natalia
  • Flores, Juana María
  • Cortazar, Ana Rosa
  • Zúñiga García, Patricia
  • Arruabarrena-Aristorena, Amaia
  • Guillaumond, Fabienne
  • Cabrera, Diana
  • Falcón Pérez, Juan M.
  • Aransay, Ana M.
  • Gomez-Muñoz, Antonio
  • Olivan Riera, Mireia
  • Morote, Juan
  • Carracedo, Arkaitz
Prostate cancer is diagnosed late in life, when co-morbidities are frequent. Among them, hypertension, hypercholesterolemia, diabetes or metabolic syndrome exhibit an elevated incidence. In turn, prostate cancer patients frequently undergo chronic pharmacological treatments that could alter disease initiation, progression and therapy response. Here we show that treatment with anti-cholesterolemic drugs, statins, at doses achieved in patients, enhance the pro-tumorigenic activity of obesogenic diets. In addition, the use of a mouse model of prostate cancer and human prostate cancer xenografts revealed that in vivo simvastatin administration alone increases prostate cancer aggressiveness. In vitro cell line systems supported the notion that this phenomenon occurs, at least in part, through the direct action on cancer cells of low doses of statins, in range of what is observed in human plasma. In sum, our results reveal a prostate cancer experimental system where statins exhibit an undesirable effect, and warrant further research to address the relevance and implications of this observation in human prostate cancer.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis

  • Palomo Irigoyen, Marta
  • Pérez Andrés, Encarni
  • Iruarrizaga Lejarreta, Marta
  • Barreira Manrique, Adrián
  • Tamayo Caro, Miguel
  • Vila Vecilla, Laura
  • Moreno Cugnon, Leire
  • Beitia, Nagore
  • Medrano, Daniela
  • Fernández Ramos, David
  • Lozano Salvatella, Juan José
  • Okawa, Satoshi
  • Lavín, José L.
  • Martín Martín, Natalia
  • Sutherland, James David
  • Guitiérez de Juan, Virginia
  • González López, Monika
  • Macías Cámara, Nuria
  • Mosén Ansorena, David
  • Laraba, Liyam
  • Hanemann, C. Oliver
  • Ercolano, Emanuela
  • Parkinson, David B.
  • Schultz, Christopher W.
  • Araúzo Bravo, Marcos J.
  • Ascensión, Alex M.
  • Gerovska, Daniela
  • Iribar, Haizea
  • Izeta, Ander
  • Pytel, Peter
  • Krastel, Philipp
  • Provenzani, Alessandro
  • Seneci, Pierfausto
  • Carrasco, Ruben D.
  • Sol, Antonio Del
  • Martínez Chantar, Maria Luz
  • Barrio, Rosa
  • Serra Arenas, Eduard
  • Lázaro García, Conxi
  • Flanagan, Adrienne M.
  • Gorospe, Myriam
  • Ratner, Nancy
  • Aransay, Ana M.
  • Carracedo, Arkaitz
  • Varela Rey, Marta
  • Woodhoo, Ashwin
Cancer cells can develop a strong addiction to discrete molecular regulators, which control the aberrant gene expression programs that drive and maintain the cancer phenotype. Here, we report the identification of the RNA-binding protein HuR/ELAVL1 as a central oncogenic driver for malignant peripheral nerve sheath tumors (MPNSTs), which are highly aggressive sarcomas that originate from cells of the Schwann cell lineage. HuR was found to be highly elevated and bound to a multitude of cancer-associated transcripts in human MPNST samples. Accordingly, genetic and pharmacological inhibition of HuR had potent cytostatic and cytotoxic effects on tumor growth, and strongly suppressed metastatic capacity in vivo. Importantly, we linked the profound tumorigenic function of HuR to its ability to simultaneously regulate multiple essential oncogenic pathways in MPNST cells, including the Wnt/beta-catenin, YAP/TAZ, RB/E2F, and BET pathways, which converge on key transcriptional networks. Given the exceptional dependency of MPNST cells on HuR for survival, proliferation, and dissemination, we propose that HuR represents a promising therapeutic target for MPNST treatment.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

  • Zabala Letona, Amaia
  • Arruabarrena-Aristorena, Amaia
  • Martín Martín, Natalia
  • Fernández Ruiz, Sonia
  • Sutherland, James David
  • Clasquin, Michelle
  • Tomas Cortazar, Julen
  • Jimenez, Jose
  • Torres, Inés de
  • Quang, Phong
  • Ximénez Embún, Pilar
  • Bago, Ruzica
  • Ugalde Olano, Aitziber
  • Loizaga Iriarte, Ana
  • Lacasa-Viscasillas, Isabel
  • Unda Urzaiz, Miguel
  • Torrano, Verónica
  • Cabrera, Diana
  • van Liempd, Sebastiaan M.
  • Cendon, Ylenia
  • Castro, Elena
  • Murray, Stuart
  • Revandkar, Ajinkya
  • Alimonti, Andrea
  • Zhang, Yinan
  • Barnett, Amelia
  • Lein, Gina
  • Pirman, David
  • Cortazar, Ana Rosa
  • Arreal, Leire
  • Prudkin, Ludmila
  • Astobiza, Ianire
  • Valcarcel Jimenez, Lorea
  • Zuñiga García, Patricia
  • Fernandez-Dominguez, Itziar
  • Piva, Marco
  • Caro Maldonado, Alfredo
  • Sánchez Mosquera, Pilar
  • Castillo Martin, Mireia
  • Serra Elizalde, Violeta
  • Beraza, Naiara
  • Gentilella, Antonio
  • Thomas, George
  • Azkargorta, Mikel
  • Elortza, Felix
  • Farràs, Rosa
  • Olmos, David
  • Efeyan, Alejo
  • Anguita, Juan
  • Muñoz, Javier
  • Falcón Pérez, Juan Manuel
  • Barrio, Rosa
  • Macarulla, Teresa
  • Mato, José M.
  • Martínez Chantar, Maria Luz
  • Cordon Cardo, Carlos
  • Aransay, Ana M.
  • Marks, Kevin
  • Baselga Torres, Josep, 1959-2021
  • Tabernero Caturla, Josep
  • Nuciforo, Paolo
  • Manning, Brendan D.
  • Marjon, Katya
  • Carracedo, Arkaitz
Activation of the PTEN-PI3K-mTORC1 pathway consolidates metabolic programs that sustain cancer cell growth and proliferation1,2. Here we show that mechanistic target of rapamycin complex 1 (mTORC1) regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. By using integrative metabolomics in a mouse model3 and human biopsies4 of prostate cancer, we identify alterations in tumours affecting the production of decarboxylated S-adenosylmethionine (dcSAM) and polyamine synthesis. Mechanistically, this metabolic rewiring stems from mTORC1-dependent regulation of S-adenosylmethionine decarboxylase 1 (AMD1) stability. This novel molecular regulation is validated in mouse and human cancer specimens. AMD1 is upregulated in human prostate cancer with activated mTORC1. Conversely, samples from a clinical trial with the mTORC1 inhibitor everolimus5 exhibit a predominant decrease in AMD1 immunoreactivity that is associated with a decrease in proliferation, in line with the requirement of dcSAM production for oncogenicity. These findings provide fundamental information about the complex regulatory landscape controlled by mTORC1 to integrate and translate growth signals into an oncogenic metabolic program.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Transcriptomic profiling of urine extracellular vesicles reveals alterations of CDH3 in prostate cancer

  • Royo, Felix
  • Zúñiga García, Patricia
  • Torrano, Verónica
  • Loizaga Iriarte, Ana
  • Sánchez Mosquera, Pilar
  • Ugalde-Olano, Aitziber
  • González, Esperanza
  • Cortazar, Ana Rosa
  • Palomo, Laura
  • Fernández-Ruiz, Sonia
  • Lacasa-Viscasillas, Isabel
  • Berdasco, María
  • Sutherland, James David
  • Barrio, Rosa
  • Zabala Letona, Amaia
  • Martín-Martín, Natalia
  • Arruabarrena-Aristorena, Amaia
  • Valcarcel Jimenez, Lorea
  • Caro Maldonado, Alfredo
  • Gonzalez-Tampan, Jorge
  • Cachi-Fuentes, Guido
  • Esteller, Manel, 1968-
  • Aransay, Ana M.
  • Unda Urzaiz, Miguel
  • Falcón Pérez, Juan Manuel
  • Carracedo, Arkaitz
Extracellular vesicles (EV) are emerging structures with promising properties for intercellular communication. In addition, the characterization of EV in biofluids is an attractive source of non-invasive diagnostic, prognostic and predictive biomarkers. Here we show that urinary EV (uEV) from prostate cancer (PCa) patients exhibit genuine and differential physical and biological properties compared to benign prostate hyperplasia (BPH). Importantly, transcriptomics characterization of uEVs led us to define the decreased abundance of Cadherin 3, type 1 (CDH3) transcript in uEV from PCa patients. Tissue and cell line analysis strongly suggested that the status of CDH3 in uEVs is a distal reflection of changes in the expression of this cadherin in the prostate tumor. CDH3 was negatively regulated at the genomic, transcriptional, and epigenetic level in PCa. Our results reveal that uEVs could represent a non-invasive tool to inform about the molecular alterations in PCa.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

PTEN mediates Notch-dependent stalk cell arrest in angiogenesis.

  • Serra, Helena
  • Chivite, Íñigo
  • Angulo Aguado, Ana
  • Soler, Adriana
  • Sutherland, James David
  • Arruabarrena-Aristorena, Amaia
  • Ragab, Anan
  • Lim, Radiance
  • Malumbres, Marcos
  • Fruttiger, Marcus
  • Potente, Michael
  • Serrano Marugán, Manuel
  • Fabra Fres, Àngels
  • Viñals Canals, Francesc
  • Casanovas i Casanovas, Oriol
  • Pandolfi, Pier Paolo
  • Bigas Salvans, Anna
  • Carracedo, Arkaitz
  • Gerhardt, Holger
  • Graupera i Garcia-Milà, Mariona
Coordinated activity of VEGF and Notch signals guides the endothelial cell (EC) specification into tip and stalk cells during angiogenesis. Notch activation in stalk cells leads to proliferation arrest via an unknown mechanism. By using gain- and loss-of-function gene-targeting approaches, here we show that PTEN is crucial for blocking stalk cell proliferation downstream of Notch, and this is critical for mouse vessel development. Endothelial deletion of PTEN results in vascular hyperplasia due to a failure to mediate Notch-induced proliferation arrest. Conversely, overexpression of PTEN reduces vascular density and abrogates the increase in EC proliferation induced by Notch blockade. PTEN is a lipid/protein phosphatase that also has nuclear phosphatase-independent functions. We show that both the catalytic and non-catalytic APC/C-Fzr1/Cdh1-mediated activities of PTEN are required for stalk cells' proliferative arrest. These findings define a Notch-PTEN signalling axis as an orchestrator of vessel density and implicate the PTEN-APC/C-Fzr1/Cdh1 hub in angiogenesis.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

In-silico gene essentiality analysis of polyamine biosynthesis reveals APRT as a potential target in cancer

  • Pey, Jon
  • San José-Eneriz, Edurne
  • Ochoa, María Carmen
  • Apaolaza, Iñigo
  • Atauri, Pedro de
  • Rubio, Angel
  • Cendoya, Xabier
  • Miranda, Estíbaliz
  • Garate, Leire
  • Cascante i Serratosa, Marta
  • Carracedo, Arkaitz
  • Agirre, Xabier
  • Prosper, Felipe
  • Planes, Francisco J.
Constraint-based modeling for genome-scale metabolic networks has emerged in the last years as a promising approach to elucidate drug targets in cancer. Beyond the canonical biosynthetic routes to produce biomass, it is of key importance to focus on metabolic routes that sustain the proliferative capacity through the regulation of other biological means in order to improve in-silico gene essentiality analyses. Polyamines are polycations with central roles in cancer cell proliferation, through the regulation of transcription and translation among other things, but are typically neglected in in silico cancer metabolic models. In this study, we analysed essential genes for the biosynthesis of polyamines. Our analysis corroborates the importance of previously known regulators of the pathway, such as Adenosylmethionine Decarboxylase 1 (AMD1) and uncovers novel enzymes predicted to be relevant for polyamine homeostasis. We focused on Adenine phosphoribosyltransferase (APRT) and demonstrated the detrimental consequence of APRT gene silencing on diferent leukaemia cell lines. Our results highlight the importance of revisiting the metabolic models used for in-silico gene essentiality analyses in order to maximize the potential for drug target identifcation in cancer
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Stratification and therapeutic potential of PML in metastatic breast cancer

  • Martín-Martín, Natalia
  • Piva, Marco
  • Urosevic, Jelena
  • Aldaz, Paula
  • Sutherland, James David
  • Fernández-Ruiz, Sonia
  • Arreal, Leire
  • Torrano, Verónica
  • Cortazar, Ana Rosa
  • Planet, Evarist
  • Guiu, Marc
  • Radosevic Robin, Nina
  • Garcia, Stephane
  • Macías, Iratxe
  • Salvador, Fernando
  • Domenici, Giacomo
  • Rueda, Oscar M.
  • Zabala Letona, Amaia
  • Arruabarrena-Aristorena, Amaia
  • Zúñiga García, Patricia
  • Caro Maldonado, Alfredo
  • Valcarcel Jimenez, Lorea
  • Sánchez Mosquera, Pilar
  • Varela Rey, Marta
  • Martínez Chantar, Maria Luz
  • Anguita, Juan
  • Ibrahim, Yasir H.
  • Scaltriti, Maurizio
  • Lawrie, Charles H.
  • Aransay, Ana M.
  • Iovanna, Juan L.
  • Baselga Torres, Josep, 1959-2021
  • Caldas, Carlos
  • Barrio, Rosa
  • Serra Elizalde, Violeta
  • Vivanco, Maria d. M.
  • Matheu, Ander
  • Gomis i Cabré, Roger
  • Carracedo, Arkaitz
Patient stratification has been instrumental for the success of targeted therapies in breast cancer. However, the molecular basis of metastatic breast cancer and its therapeutic vulnerabilities remain poorly understood. Here we show that PML is a novel target in aggressive breast cancer. The acquisition of aggressiveness and metastatic features in breast tumours is accompanied by the elevated PML expression and enhanced sensitivity to its inhibition. Interestingly, we find that STAT3 is responsible, at least in part, for the transcriptional upregulation of PML in breast cancer. Moreover, PML targeting hampers breast cancer initiation and metastatic seeding. Mechanistically, this biological activity relies on the regulation of the stem cell gene SOX9 through interaction of PML with its promoter region. Altogether, we identify a novel pathway sustaining breast cancer aggressiveness that can be therapeutically exploited in combination with PML-based stratification.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Loss of Tribbles pseudokinase-3 promotes Akt-driven tumorigenesis via FOXO inactivation

  • Salazar, María
  • Pérez-Gómez, Eduardo
  • Flores, Juana María
  • Quintanilla, Miguel
  • Sánchez, Cristina
  • Carracedo, Ángel
  • Velasco, Guillermo
et al., Tribbles pseudokinase-3 (TRIB3) has been proposed to act as an inhibitor of AKT although the precise molecular basis of this activity and whether the loss of TRIB3 contributes to cancer initiation and progression remain to be clarified. In this study, by using a wide array of in vitro and in vivo approaches, including a Trib3 knockout mouse, we demonstrate that TRIB3 has a tumor-suppressing role. We also find that the mechanism by which TRIB3 loss enhances tumorigenesis relies on the dysregulation of the phosphorylation of AKT by the mTORC2 complex, which leads to an enhanced phosphorylation of AKT on Ser473 and the subsequent hyperphosphorylation and inactivation of the transcription factor FOXO3. These observations support the notion that loss of TRIB3 is associated with a more aggressive phenotype in various types of tumors by enhancing the activity of the mTORC2/AKT/FOXO axis., This work was supported by grants from Spanish Ministry of Economy and Competitiveness (MINECO) and Fondo Europeo de Desarrollo Regional (FEDER) (PS09/01401; PI12/02248, FR2009-0052 and IT2009-0053 to GV), Comunidad de Madrid (S2011/BMD-2308 to MG), Fundación Mutua Madrileña (AP101042012 to GV) and Breast Cancer Campaign (2012NovSP033 to EKT and GV). Purchase of the TRIB3-deficient mice (LEXKO-1947) line was funded by the Wellcome Trust. MS was recipient of a fellowship from Spanish Ministry of Education and Science (MEC), a research formation contract from Comunidad de Madrid and a Postdoctoral Research Contract from Fundación Científica Asociación Española Contra el Cáncer (AECC); ML was sequentially the recipient of a ‘Juan de la Cierva’ contract, a postdoctoral contract from Spanish Ministry of Education and Science (MEC) and a postdoctoral contract from Comunidad de Madrid. AC is supported by an ERC StG (336343), the Ramón y Cajal award (Spanish Ministry of Education), the Basque Department of Industry, Tourism and Trade (Etortek), Marie Curie Reintegration grant (277043), Movember Global Action Plan, ISCIII (PI10/01484) and the Basque Government of health (2012111086) and education (PI2012-03). EPG was the recipient of a Postdoctoral Research Contract from AECC., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The immunosuppressive effect of the tick protein, Salp15, is long-lasting and persists in a murine model of hematopoietic transplant

  • Tomás-Cortázar, Julen
  • Martín-Ruiz, Itziar
  • Barriales, Diego
  • Pascual-Itoiz, Miguel Ángel
  • Gutiérrez de Juan, Virginia
  • Caro-Maldonado, Alfredo
  • Merino, Nekane
  • Marina, Alberto
  • Blanco, Francisco J.
  • Flores, Juana María
  • Sutherland, James D.
  • Barrio, Rosa
  • Rojas, Adriana
  • Martínez-Chantar, María Luz
  • Carracedo, Arkaitz
  • Simó, Carolina
  • García-Cañas, Virginia
  • Abecia, Leticia
  • Lavín, José Luis
  • Aransay, Ana M.
  • Rodríguez, Héctor
  • Anguita, Juan
Salp15, a salivary protein of Ixodes ticks, inhibits the activation of naïve CD4 T cells. Treatment with Salp15 results in the inhibition of early signaling events and the production of the autocrine growth factor, interleukin-2. The fate of the CD4 T cells activated in the presence of Salp15 or its long-term effects are, however, unknown. We now show that Salp15 binding to CD4 is persistent and induces a long-lasting immunomodulatory effect. The activity of Salp15 results in sustained diminished cross-antigenic antibody production even after interruption of the treatment with the protein. Transcriptionally, the salivary protein provokes an acute effect that includes known activation markers, such as Il2 or Cd44, and that fades over time. The long-term effects exerted by Salp15 do not involve the induction of either anergy traits nor increased populations of regulatory T cells. Similarly, the treatment with Salp15 does not result in B cell anergy or the generation of myeloid suppressor cells. However, Salp15 induces the increased expression of the ectoenzyme, CD73, in regulatory T cells and increased production of adenosine. Our study provides a profound characterization of the immunomodulatory activity of Salp15 and suggests that its long-term effects are due to the specific regulation of CD73. Introduction, Supported by grants from the Department of Education of the Basque Government (PI2013-49 to JA and PI2012-42 to RB). JA is funded by the European Union (Grant Agreement number 602272). AMA and JLL’s work was supported by the Basque Department of Industry, Tourism and Trade (Etortek and Elkartek Programs), the Innovation Technology Department of Bizkaia and the CIBERehd Network. The work of AC is supported by a Ramón y Cajal award, the Basque Department of Industry, Tourism and Trade (Etortek), ISCIII (PI13/00031), FERO VIII Fellowship, the BBVA foundation, MINECO (SAF2016-79381-R) and the European Research Council Starting Grant (336343). CIBERonc was co-funded with FEDER funds. AC-M was funded by a Juan de la Cierva program award and the European Union MSCA program (CIG 660191). RB was funded by MINECO grants BFU2011-25986 and BFU2014-52282-P and the Consolider Program (BFU2014-57703-REDC). FJB was funded by a MINECO grant (CTQ2014-56966-R). D.B. is funded by a MINECO FPI fellowship. We thank the MINECO for the Severo Ochoa Excellence accreditation (SEV-2016-0644)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Multiplex SERS Detection of Metabolic Alterations in Tumor Extracellular Media

  • Plou, Javier
  • García, Isabel
  • Charconnet, Mathias
  • Astobiza, Ianire
  • García Astrain, Clara
  • Matricardi, Cristiano
  • Mihi, Agustín
  • Carracedo, Arkaitz
  • Liz-Marzán, Luis Manuel
The composition and intercellular interactions of tumor cells in the tissues dictate the biochemical and metabolic properties of the tumor microenvironment. The metabolic rewiring has a profound impact on the properties of the microenvironment, to an extent that monitoring such perturbations could harbor diagnostic and therapeutic relevance. A growing interest in these phenomena has inspired the development of novel technologies with sufficient sensitivity and resolution to monitor metabolic alterations in the tumor microenvironment. In this context, surface‐enhanced Raman scattering (SERS) can be used for the label‐free detection and imaging of diverse molecules of interest among extracellular components. Herein, the application of nanostructured plasmonic substrates comprising Au nanoparticles, self‐assembled as ordered superlattices, to the precise SERS detection of selected tumor metabolites, is presented. The potential of this technology is first demonstrated through the analysis of kynurenine, a secreted immunomodulatory derivative of the tumor metabolism and the related molecules tryptophan and purine derivatives. SERS facilitates the unambiguous identification of trace metabolites and allows the multiplex detection of their characteristic fingerprints under different conditions. Finally, the effective plasmonic SERS substrate is combined with a hydrogel‐based three‐dimensional cancer model, which recreates the tumor microenvironment, for the real‐time imaging of metabolite alterations and cytotoxic effects on tumor cells., J.P. acknowledges an FPU fellowship from the Spanish Ministry of Science, Innovation and Universities. L.M.L.‐M. acknowledges funding from the European Research Council (ERC AdG 787510, 4DbioSERS) and the Maria de Maeztu Units of Excellence Program from the Spanish State Research Agency (Grant No. MDM‐2017‐0720). C.G.‐A. acknowledges a Juan de la Cierva Fellowship from the Spanish Ministry of Science, Innovation and Universities (FJCI‐2016‐28887). The authors thank Dr. J. Calvo and Dr. D. Otaegui at CIC biomaGUNE for support with LC/ESI‐HRMS measurements. The work of A.C. was supported by the Basque Department of Industry, Tourism and Trade (Elkartek), and the department of education (IKERTALDE IT1106‐16, also participated by A. Gomez‐Muñoz), the BBVA foundation, the MINECO (SAF2016‐79381‐R (FEDER/EU); Severo Ochoa Excellence Program SEV‐2016‐0644‐18‐1; Excellence Networks SAF2016‐81975‐REDT), European Training Networks Project (H2020‐MSCA‐ITN‐308 2016 721532), the AECC (IDEAS175CARR, GCTRA18006CARR), La Caixa Foundation (HR17‐00094), and the European Research Council (starting Grant 336343, PoC 754627). CIBERONC was co‐funded with FEDER funds and funded by ISCIII. A.M. acknowledges funding from the European Research Council (Consolidator Grant 819242) and the Spanish Ministry of Science, Innovation and Universities for the excellence program SEV‐2015‐0496.J.P. acknowledges an FPU fellowship from the Spanish Ministry of Science, Innovation and Universities. L.M.L.‐M. acknowledges funding from the European Research Council (ERC AdG 787510, 4DbioSERS) and the Maria de Maeztu Units of Excellence Program from the Spanish State Research Agency (Grant No. MDM‐2017‐0720). C.G.‐A. acknowledges a Juan de la Cierva Fellowship from the Spanish Ministry of Science, Innovation and Universities (FJCI‐2016‐28887). The authors thank Dr. J. Calvo and Dr. D. Otaegui at CIC biomaGUNE for support with LC/ESI‐HRMS measurements. The work of A.C. was supported by the Basque Department of Industry, Tourism and Trade (Elkartek), and the department of education (IKERTALDE IT1106‐16, also participated by A. Gomez‐Muñoz), the BBVA foundation, the MINECO (SAF2016‐79381‐R (FEDER/EU); Severo Ochoa Excellence Program SEV‐2016‐0644‐18‐1; Excellence Networks SAF2016‐81975‐REDT), European Training Networks Project (H2020‐MSCA‐ITN‐308 2016 721532), the AECC (IDEAS175CARR, GCTRA18006CARR), La Caixa Foundation (HR17‐00094), and the European Research Council (starting Grant 336343, PoC 754627). CIBERONC was co‐funded with FEDER funds and funded by ISCIII. A.M. acknowledges funding from the European Research Council (Consolidator Grant 819242) and the Spanish Ministry of Science, Innovation and Universities for the excellence program SEV‐2015‐0496., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Genomic and Functional Regulation of TRIB1 Contributes to Prostate Cancer Pathogenesis

  • Shahrouzi, Parastoo
  • Astobiza, Ianire
  • Cortázar, Ana R.
  • Torrano, Verónica
  • Macchia, Alice
  • Flores, Juana María
  • Niespolo, Chiara
  • Mendizábal, Isabel
  • Caloto, Rubén
  • Ercilla, Amaia
  • Camacho, Laura
  • Arreal, Leire
  • Bizkarguenaga, Maider
  • Martínez-Chantar, María Luz
  • Bustelo, Xosé R.
  • Berra, Edurne
  • Kiss-Toth, Endre
  • Velasco, Guillermo
  • Zabala-Letona, Amaia
  • Carracedo, Arkaitz
© 2020 by the authors., Prostate cancer is the most frequent malignancy in European men and the second worldwide. One of the major oncogenic events in this disease includes amplification of the transcription factor cMYC. Amplification of this oncogene in chromosome 8q24 occurs concomitantly with the copy number increase in a subset of neighboring genes and regulatory elements, but their contribution to disease pathogenesis is poorly understood. Here we show that TRIB1 is among the most robustly upregulated coding genes within the 8q24 amplicon in prostate cancer. Moreover, we demonstrate that TRIB1 amplification and overexpression are frequent in this tumor type. Importantly, we find that, parallel to its amplification, TRIB1 transcription is controlled by cMYC. Mouse modeling and functional analysis revealed that aberrant TRIB1 expression is causal to prostate cancer pathogenesis. In sum, we provide unprecedented evidence for the regulation and function of TRIB1 in prostate cancer., We are grateful to the Carracedo lab for valuable input, to Ana M. Aransay and F. Elortza for technical advice. P.S. was funded by the European Training Networks Project (H2020-MSCA-ITN-308 2016 721532). V.T. is funded by Fundación Vasca de Innovación e Investigación Sanitarias, BIOEF (BIO15/CA/052), the AECC J.P. Bizkaia, the Basque Department of Health (2016111109) and the MICINN RTI2018-097267-B-I00. A. Macchia was funded by a FPI predoctoral fellowship from MICINN (PRE2018-083607). EB is funded by the MICINN (BFU2016-76872-R (FEDER/EU), PID2019-108112RB-I00, Severo Ochoa Excellence Accreditation SEV-2016-0644 and Excellence Networks SAF2017-90794-REDT). The work of A. Carracedo is supported by the Basque Department of Industry, Tourism and Trade (Elkartek), the department of education (IKERTALDE IT1106-16) and health (RIS3), the BBVA foundation and the MICINN (SAF2016-79381-R (FEDER/EU; PID2019-108787RB-I00) Severo Ochoa Excellence Accreditation SEV-2016-0644 and Excellence Networks SAF2016-81975-REDT and RED2018-102769-T), European Training Networks Project (H2020-MSCA-ITN-308 2016 721532), the AECC (IDEAS175CARR, GCTRA18006CARR), La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17/ and the European Research Council (Starting Grant 336343, Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and funded by ISCIII.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cancertool: A visualization and representation interface to exploit cancer datasets

  • Cortázar, Ana R.
  • Torrano, Verónica
  • Martín-Martín, Natalia
  • Caro-Maldonado, Alfredo
  • Camacho, Laura
  • Hermanova, Ivana
  • Guruceaga, Elizabeth
  • Lorenzo-Martín, L. Francisco
  • Caloto, Rubén
  • Gomis, Roger R.
  • Apaolaza, Iñigo
  • Quesada, Víctor
  • Trka, Jan
  • Gómez-Muñoz, Antonio
  • Vincent, Silvestre
  • Bustelo, Xosé R.
  • Planes, Francisco J.
  • Aransay, Ana M.
  • Carracedo, Arkaitz
With the advent of OMICs technologies, both individual research groups and consortia have spear-headed the characterization of human samples of multiple pathophysiologic origins, resulting in thousands of archived genomes and transcriptomes. Although a variety of web tools are now available to extract information from OMICs data, their utility has been limited by the capacity of nonbioinformatician researchers to exploit the information. To address this problem, we have developed CANCERTOOL, a web-based interface that aims to overcome the major limitations of public transcriptomics dataset analysis for highly prevalent types of cancer (breast, prostate, lung, and colorectal). CANCERTOOL provides rapid and comprehensive visualization of gene expression data for the gene(s) of interest in well-annotated cancer datasets. This visualization is accompanied by generation of reports customized to the interest of the researcher (e.g., editable figures, detailed statistical analyses, and access to raw data for reanalysis). It also carries out gene-to-gene correlations in multiple datasets at the same time or using preset patient groups. Finally, this new tool solves the time-consuming task of performing functional enrichment analysis with gene sets of interest using up to 11 different databases at the same time. Collectively, CANCERTOOL represents a simple and freely accessible interface to interrogate well-annotated datasets and obtain publishable representations that can contribute to refinement and guidance of cancer-related investigations at all levels of hypotheses and design., We are grateful to Iñaki Lazaro for the design of the tumor type logos, Evarist Planet and Antoni Berenguer for insightful discussions, and the Carracedo lab for valuable input. V. Torrano is funded by Fundación Vasca de Innovación e Investigación Sanitarias, BIOEF (BIO15/CA/052), the AECC J.P. Bizkaia and the Basque Department of Health (2016111109). The work of A. Carracedo is supported by the Basque Department of Industry, Tourism and Trade (Etortek) and the Department of Education (IKERTALDE IT1106-16, also participated by A. Gomez-Muñoz), the BBVA Foundation, the MINECO [SAF2016-79381-R (FEDER/EU)]; Severo Ochoa Excellence Accreditation SEV-2016-0644; Excellence Networks (SAF2016-81975-REDT), European Training Networks Project (H2020-MSCA-ITN-308 2016 721532), the AECC IDEAS16 (IDEAS175CARR), and the European Research Council (Starting Grant 336343, PoC 754627). CIBERONC was cofunded with FEDER funds. The work of A. Aransay is supported by the Basque Department of Industry, Tourism and Trade (Etortek and Elkartek Programs), the Innovation Technology Department of Bizkaia County, CIBERehd Network, and Spanish MINECO the Severo Ochoa Excellence Accreditation (SEV-2016-0644). I. Apaolaza is funded by a Basque Government predoctoral grant (PRE_2017_2_0028). X.R. Bustelo is supported by grants from the Castilla-León Government (BIO/SA01/15, CSI049U16), Spanish Ministry of Economy and Competitiveness (MINECO; SAF2015-64556-R), Worldwide Cancer Research (14-1248), Ramón Areces Foundation, and the Spanish Society against Cancer (GC16173472GARC). Funding from MINECO to X.R. Bustelo is partially contributed by the European Regional Development Fund. The work of F.J. Planes is supported by the MINECO (BIO2016-77998-R) and ELKARTEK Programme of the Basque Government (KK-2016/00026).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

  • Zabala Letona, Amaia
  • Arruabarrena-Aristorena, Amaia
  • Martín Martín, Natalia
  • Fernández Ruiz, Sonia
  • Sutherland, James David
  • Clasquin, Michelle
  • Tomas Cortazar, Julen
  • Jimenez, Jose
  • Torres, Inés de
  • Quang, Phong
  • Ximénez Embún, Pilar
  • Bago, Ruzica
  • Ugalde Olano, Aitziber
  • Loizaga Iriarte, Ana
  • Lacasa-Viscasillas, Isabel
  • Unda Urzaiz, Miguel
  • Torrano, Verónica
  • Cabrera, Diana
  • van Liempd, Sebastiaan M.
  • Cendon, Ylenia
  • Castro, Elena
  • Murray, Stuart
  • Revandkar, Ajinkya
  • Alimonti, Andrea
  • Zhang, Yinan
  • Barnett, Amelia
  • Lein, Gina
  • Pirman, David
  • Cortazar, Ana Rosa
  • Arreal, Leire
  • Prudkin, Ludmila
  • Astobiza, Ianire
  • Valcarcel Jimenez, Lorea
  • Zuñiga García, Patricia
  • Fernandez-Dominguez, Itziar
  • Piva, Marco
  • Caro Maldonado, Alfredo
  • Sánchez Mosquera, Pilar
  • Castillo Martin, Mireia
  • Serra Elizalde, Violeta
  • Beraza, Naiara
  • Gentilella, Antonio
  • Thomas, George
  • Azkargorta, Mikel
  • Elortza, Felix
  • Farràs, Rosa
  • Olmos, David
  • Efeyan, Alejo
  • Anguita, Juan
  • Muñoz, Javier
  • Falcón Pérez, Juan Manuel
  • Barrio, Rosa
  • Macarulla, Teresa
  • Mato, José M.
  • Martínez Chantar, Maria Luz
  • Cordon Cardo, Carlos
  • Aransay, Ana M.
  • Marks, Kevin
  • Baselga Torres, Josep, 1959-2021
  • Tabernero Caturla, Josep
  • Nuciforo, Paolo
  • Manning, Brendan D.
  • Marjon, Katya
  • Carracedo, Arkaitz
Activation of the PTEN-PI3K-mTORC1 pathway consolidates metabolic programs that sustain cancer cell growth and proliferation1,2. Here we show that mechanistic target of rapamycin complex 1 (mTORC1) regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. By using integrative metabolomics in a mouse model3 and human biopsies4 of prostate cancer, we identify alterations in tumours affecting the production of decarboxylated S-adenosylmethionine (dcSAM) and polyamine synthesis. Mechanistically, this metabolic rewiring stems from mTORC1-dependent regulation of S-adenosylmethionine decarboxylase 1 (AMD1) stability. This novel molecular regulation is validated in mouse and human cancer specimens. AMD1 is upregulated in human prostate cancer with activated mTORC1. Conversely, samples from a clinical trial with the mTORC1 inhibitor everolimus5 exhibit a predominant decrease in AMD1 immunoreactivity that is associated with a decrease in proliferation, in line with the requirement of dcSAM production for oncogenicity. These findings provide fundamental information about the complex regulatory landscape controlled by mTORC1 to integrate and translate growth signals into an oncogenic metabolic program.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

PTEN mediates Notch-dependent stalk cell arrest in angiogenesis.

  • Serra, Helena
  • Chivite, Íñigo
  • Angulo Aguado, Ana
  • Soler, Adriana
  • Sutherland, James David
  • Arruabarrena-Aristorena, Amaia
  • Ragab, Anan
  • Lim, Radiance
  • Malumbres, Marcos
  • Fruttiger, Marcus
  • Potente, Michael
  • Serrano Marugán, Manuel
  • Fabra Fres, Àngels
  • Viñals Canals, Francesc
  • Casanovas i Casanovas, Oriol
  • Pandolfi, Pier Paolo
  • Bigas Salvans, Anna
  • Carracedo, Arkaitz
  • Gerhardt, Holger
  • Graupera i Garcia-Milà, Mariona
Coordinated activity of VEGF and Notch signals guides the endothelial cell (EC) specification into tip and stalk cells during angiogenesis. Notch activation in stalk cells leads to proliferation arrest via an unknown mechanism. By using gain- and loss-of-function gene-targeting approaches, here we show that PTEN is crucial for blocking stalk cell proliferation downstream of Notch, and this is critical for mouse vessel development. Endothelial deletion of PTEN results in vascular hyperplasia due to a failure to mediate Notch-induced proliferation arrest. Conversely, overexpression of PTEN reduces vascular density and abrogates the increase in EC proliferation induced by Notch blockade. PTEN is a lipid/protein phosphatase that also has nuclear phosphatase-independent functions. We show that both the catalytic and non-catalytic APC/C-Fzr1/Cdh1-mediated activities of PTEN are required for stalk cells' proliferative arrest. These findings define a Notch-PTEN signalling axis as an orchestrator of vessel density and implicate the PTEN-APC/C-Fzr1/Cdh1 hub in angiogenesis.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer

  • Hermanova, Ivana
  • Zúñiga García, Patricia
  • Caro Maldonado, Alfredo
  • Fernandez Ruiz, Sonia
  • Salvador, Fernando
  • Martín Martín, Natalia
  • Zabala Letona, Amaia
  • Nuñez Olle, Marc
  • Torrano, Verónica
  • Camacho, Laura
  • Lizcano, José Miguel
  • Talamillo, Ana
  • Carreira, Suzanne
  • Gurel, Bora
  • Cortazar, Ana Rosa
  • Guiu, Marc
  • López, Jose I.
  • Martínez Romero, Anabel
  • Astobiza, Ianire
  • Valcarcel Jimenez, Lorea
  • Lorente, Mar
  • Arruabarrena-Aristorena, Amaia
  • Velasco, Guillermo
  • Gomez Muñoz, Antonio
  • Suarez Cabrera, Cristian
  • Lodewijk, Iris
  • Flores, Juana M.
  • Sutherland, James David
  • Barrio, Rosa
  • Bono, Johann Sebastian de
  • Paramio, Jesús M.
  • Trka, Jan
  • Graupera i Garcia-Milà, Mariona
  • Gomis i Cabré, Roger
  • Carracedo, Arkaitz
Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model an aggressive form of prostate cancer and show the unconventional association of LKB1 dosage to prostate tumorigenesis. Whereas loss of Lkbl alone in the murine prostate epithelium was inconsequential for tumorigenesis, its combination with an oncogenic insult, illustrated by Pten heterozygosity, elicited lethal metastatic prostate cancer. Despite the low frequency of LKB1 deletion in patients, this event was significantly enriched in lung metastasis. Modeling the role of LKB1 in cellular systems revealed that the residual activity retained in a reported kinase-dead form, LKB1(K781), was sufficient to hamper tumor aggressiveness and metastatic dissemination. Our data suggest that prostate cells can function normally with low activity of LKB1, whereas its complete absence influences prostate cancer pathogenesis and dissemination.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis

  • Palomo Irigoyen, Marta
  • Pérez Andrés, Encarni
  • Iruarrizaga Lejarreta, Marta
  • Barreira Manrique, Adrián
  • Tamayo Caro, Miguel
  • Vila Vecilla, Laura
  • Moreno Cugnon, Leire
  • Beitia, Nagore
  • Medrano, Daniela
  • Fernández Ramos, David
  • Lozano Salvatella, Juan José
  • Okawa, Satoshi
  • Lavín, José L.
  • Martín Martín, Natalia
  • Sutherland, James David
  • Guitiérez de Juan, Virginia
  • González López, Monika
  • Macías Cámara, Nuria
  • Mosén Ansorena, David
  • Laraba, Liyam
  • Hanemann, C. Oliver
  • Ercolano, Emanuela
  • Parkinson, David B.
  • Schultz, Christopher W.
  • Araúzo Bravo, Marcos J.
  • Ascensión, Alex M.
  • Gerovska, Daniela
  • Iribar, Haizea
  • Izeta, Ander
  • Pytel, Peter
  • Krastel, Philipp
  • Provenzani, Alessandro
  • Seneci, Pierfausto
  • Carrasco, Ruben D.
  • Sol, Antonio Del
  • Martínez Chantar, Maria Luz
  • Barrio, Rosa
  • Serra Arenas, Eduard
  • Lázaro García, Conxi
  • Flanagan, Adrienne M.
  • Gorospe, Myriam
  • Ratner, Nancy
  • Aransay, Ana M.
  • Carracedo, Arkaitz
  • Varela Rey, Marta
  • Woodhoo, Ashwin
Cancer cells can develop a strong addiction to discrete molecular regulators, which control the aberrant gene expression programs that drive and maintain the cancer phenotype. Here, we report the identification of the RNA-binding protein HuR/ELAVL1 as a central oncogenic driver for malignant peripheral nerve sheath tumors (MPNSTs), which are highly aggressive sarcomas that originate from cells of the Schwann cell lineage. HuR was found to be highly elevated and bound to a multitude of cancer-associated transcripts in human MPNST samples. Accordingly, genetic and pharmacological inhibition of HuR had potent cytostatic and cytotoxic effects on tumor growth, and strongly suppressed metastatic capacity in vivo. Importantly, we linked the profound tumorigenic function of HuR to its ability to simultaneously regulate multiple essential oncogenic pathways in MPNST cells, including the Wnt/beta-catenin, YAP/TAZ, RB/E2F, and BET pathways, which converge on key transcriptional networks. Given the exceptional dependency of MPNST cells on HuR for survival, proliferation, and dissemination, we propose that HuR represents a promising therapeutic target for MPNST treatment.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Stratification and therapeutic potential of PML in metastatic breast cancer

  • Martín-Martín, Natalia
  • Piva, Marco
  • Urosevic, Jelena
  • Aldaz, Paula
  • Sutherland, James David
  • Fernández-Ruiz, Sonia
  • Arreal, Leire
  • Torrano, Verónica
  • Cortazar, Ana Rosa
  • Planet, Evarist
  • Guiu, Marc
  • Radosevic Robin, Nina
  • Garcia, Stephane
  • Macías, Iratxe
  • Salvador, Fernando
  • Domenici, Giacomo
  • Rueda, Oscar M.
  • Zabala Letona, Amaia
  • Arruabarrena-Aristorena, Amaia
  • Zúñiga García, Patricia
  • Caro Maldonado, Alfredo
  • Valcarcel Jimenez, Lorea
  • Sánchez Mosquera, Pilar
  • Varela Rey, Marta
  • Martínez Chantar, Maria Luz
  • Anguita, Juan
  • Ibrahim, Yasir H.
  • Scaltriti, Maurizio
  • Lawrie, Charles H.
  • Aransay, Ana M.
  • Iovanna, Juan L.
  • Baselga Torres, Josep, 1959-2021
  • Caldas, Carlos
  • Barrio, Rosa
  • Serra Elizalde, Violeta
  • Vivanco, Maria d. M.
  • Matheu, Ander
  • Gomis i Cabré, Roger
  • Carracedo, Arkaitz
Patient stratification has been instrumental for the success of targeted therapies in breast cancer. However, the molecular basis of metastatic breast cancer and its therapeutic vulnerabilities remain poorly understood. Here we show that PML is a novel target in aggressive breast cancer. The acquisition of aggressiveness and metastatic features in breast tumours is accompanied by the elevated PML expression and enhanced sensitivity to its inhibition. Interestingly, we find that STAT3 is responsible, at least in part, for the transcriptional upregulation of PML in breast cancer. Moreover, PML targeting hampers breast cancer initiation and metastatic seeding. Mechanistically, this biological activity relies on the regulation of the stem cell gene SOX9 through interaction of PML with its promoter region. Altogether, we identify a novel pathway sustaining breast cancer aggressiveness that can be therapeutically exploited in combination with PML-based stratification.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Transcriptomic profiling of urine extracellular vesicles reveals alterations of CDH3 in prostate cancer

  • Royo, Felix
  • Zúñiga García, Patricia
  • Torrano, Verónica
  • Loizaga Iriarte, Ana
  • Sánchez Mosquera, Pilar
  • Ugalde-Olano, Aitziber
  • González, Esperanza
  • Cortazar, Ana Rosa
  • Palomo, Laura
  • Fernández-Ruiz, Sonia
  • Lacasa-Viscasillas, Isabel
  • Berdasco, María
  • Sutherland, James David
  • Barrio, Rosa
  • Zabala Letona, Amaia
  • Martín-Martín, Natalia
  • Arruabarrena-Aristorena, Amaia
  • Valcarcel Jimenez, Lorea
  • Caro Maldonado, Alfredo
  • Gonzalez-Tampan, Jorge
  • Cachi-Fuentes, Guido
  • Esteller, Manel, 1968-
  • Aransay, Ana M.
  • Unda Urzaiz, Miguel
  • Falcón Pérez, Juan Manuel
  • Carracedo, Arkaitz
Extracellular vesicles (EV) are emerging structures with promising properties for intercellular communication. In addition, the characterization of EV in biofluids is an attractive source of non-invasive diagnostic, prognostic and predictive biomarkers. Here we show that urinary EV (uEV) from prostate cancer (PCa) patients exhibit genuine and differential physical and biological properties compared to benign prostate hyperplasia (BPH). Importantly, transcriptomics characterization of uEVs led us to define the decreased abundance of Cadherin 3, type 1 (CDH3) transcript in uEV from PCa patients. Tissue and cell line analysis strongly suggested that the status of CDH3 in uEVs is a distal reflection of changes in the expression of this cadherin in the prostate tumor. CDH3 was negatively regulated at the genomic, transcriptional, and epigenetic level in PCa. Our results reveal that uEVs could represent a non-invasive tool to inform about the molecular alterations in PCa.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Low-dose statin treatment increases prostate cancer aggressiveness

  • Caro Maldonado, Alfredo
  • Camacho, Laura
  • Zabala Letona, Amaia
  • Torrano, Verónica
  • Fernández Ruiz, Sonia
  • Zamacola-Bascaran, Kepa
  • Arreal, Leire
  • Valcárcel-Jiménez, Lorea
  • Martín-Martín, Natalia
  • Flores, Juana María
  • Cortazar, Ana Rosa
  • Zúñiga García, Patricia
  • Arruabarrena-Aristorena, Amaia
  • Guillaumond, Fabienne
  • Cabrera, Diana
  • Falcón Pérez, Juan M.
  • Aransay, Ana M.
  • Gomez-Muñoz, Antonio
  • Olivan Riera, Mireia
  • Morote, Juan
  • Carracedo, Arkaitz
Prostate cancer is diagnosed late in life, when co-morbidities are frequent. Among them, hypertension, hypercholesterolemia, diabetes or metabolic syndrome exhibit an elevated incidence. In turn, prostate cancer patients frequently undergo chronic pharmacological treatments that could alter disease initiation, progression and therapy response. Here we show that treatment with anti-cholesterolemic drugs, statins, at doses achieved in patients, enhance the pro-tumorigenic activity of obesogenic diets. In addition, the use of a mouse model of prostate cancer and human prostate cancer xenografts revealed that in vivo simvastatin administration alone increases prostate cancer aggressiveness. In vitro cell line systems supported the notion that this phenomenon occurs, at least in part, through the direct action on cancer cells of low doses of statins, in range of what is observed in human plasma. In sum, our results reveal a prostate cancer experimental system where statins exhibit an undesirable effect, and warrant further research to address the relevance and implications of this observation in human prostate cancer.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

In-silico gene essentiality analysis of polyamine biosynthesis reveals APRT as a potential target in cancer

  • Pey, Jon
  • San José-Eneriz, Edurne
  • Ochoa, María Carmen
  • Apaolaza, Iñigo
  • Atauri, Pedro de
  • Rubio, Angel
  • Cendoya, Xabier
  • Miranda, Estíbaliz
  • Garate, Leire
  • Cascante i Serratosa, Marta
  • Carracedo, Arkaitz
  • Agirre, Xabier
  • Prosper, Felipe
  • Planes, Francisco J.
Constraint-based modeling for genome-scale metabolic networks has emerged in the last years as a promising approach to elucidate drug targets in cancer. Beyond the canonical biosynthetic routes to produce biomass, it is of key importance to focus on metabolic routes that sustain the proliferative capacity through the regulation of other biological means in order to improve in-silico gene essentiality analyses. Polyamines are polycations with central roles in cancer cell proliferation, through the regulation of transcription and translation among other things, but are typically neglected in in silico cancer metabolic models. In this study, we analysed essential genes for the biosynthesis of polyamines. Our analysis corroborates the importance of previously known regulators of the pathway, such as Adenosylmethionine Decarboxylase 1 (AMD1) and uncovers novel enzymes predicted to be relevant for polyamine homeostasis. We focused on Adenine phosphoribosyltransferase (APRT) and demonstrated the detrimental consequence of APRT gene silencing on diferent leukaemia cell lines. Our results highlight the importance of revisiting the metabolic models used for in-silico gene essentiality analyses in order to maximize the potential for drug target identifcation in cancer
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

RARRES3 suppresses breast cancer lung metastasis by regulating adhesion and differentiation

  • Morales, Mònica
  • Arenas, Enrique J.|||0000-0001-7076-2666
  • Urosevic, Jelena
  • Guiu, Marc|||0000-0002-7083-986X
  • Fernández Mostaza, Esther|||0000-0002-2335-0674
  • Planet, Evarist
  • Fenwick, Robert Bryn
  • Fernández Ruiz, Sonia
  • Salvatella, Xavier|||0000-0002-8371-4185
  • Reverter Cendrós, David|||0000-0002-5347-0992
  • Carracedo, Arkaitz|||0000-0001-5957-1260
  • Massagué, Joan
  • Gomis, Roger R.|||0000-0001-6473-2858
In estrogen receptor-negative breast cancer patients, metastatic relapse usually occurs in the lung and is responsible for the fatal outcome of the disease. Thus, a better understanding of the biology of metastasis is needed. In particular, biomarkers to identify patients that are at risk of lung metastasis could open the avenue for new therapeutic opportunities. Here we characterize the biological activity of RARRES3, a new metastasis suppressor gene whose reduced expression in the primary breast tumors identifies a subgroup of patients more likely to develop lung metastasis. We show that RARRES3 downregulation engages metastasis-initiating capabilities by facilitating adhesion of the tumor cells to the lung parenchyma. In addition, impaired tumor cell differentiation due to the loss of RARRES3 phospholipase A1/A2 activity also contributes to lung metastasis. Our results establish RARRES3 downregulation as a potential biomarker to identify patients at high risk of lung metastasis who might benefit from a differentiation treatment in the adjuvant programme.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

  • Zabala-Letona, Amaia
  • Arruabarrena-Aristorena, Amaia|||0000-0002-1636-3944
  • Martín Martín, Natalia
  • Fernández Ruiz, Sonia
  • Sutherland, James D.|||0000-0003-3229-793X
  • Clasquin, Michelle
  • Tomás Cortázar, Julen
  • Jiménez, José
  • Torres Ramírez, Inés Ma. de
  • Quang, Phong
  • Ximénez-Embún, Pilar|||0000-0002-2582-9443
  • Bago, Ruzica
  • Ugalde Olano, Aitziber
  • Loizaga Iriarte, Ana
  • Lacasa-Viscasillas, Isabel
  • Unda, Miguel
  • Torrano, Verónica
  • Cabrera, Diana
  • van Liempd, Sebastiaan M.
  • Cendon, Ylenia
  • Castro, Elena|||0000-0002-3691-6454
  • Murray, Stuart
  • Revandkar, Ajinkya
  • Alimonti, Andrea
  • Zhang, Yinan
  • Barnett, Amelia
  • Lein, Gina
  • Pirman, David
  • Cortazar, Ana Rosa|||0000-0002-7082-5695
  • Arreal, Leire
  • Prudkin, Ludmila
  • Astobiza, Ianire|||0000-0002-7142-7066
  • Valcarcel-Jimenez, Lorea
  • Zúñiga-García, Patricia
  • Fernández Domínguez, Itziar
  • Piva, Marco
  • Caro-Maldonado, Alfredo|||0000-0002-5431-7949
  • Sánchez Mosquera, Pilar
  • Castillo Martín, Mireia
  • Serra, Violeta|||0000-0001-6620-1065
  • Beraza, Naiara
  • Gentilella, Antonio|||0000-0002-6830-2086
  • Thomas, George|||0000-0002-1236-1714
  • Azkargorta, Mikel
  • Elortza, Felix|||0000-0001-8839-5438
  • Farràs, Rosa
  • Olmos, David
  • Efeyan, Alejo
  • Anguita, Juan
  • Muñoz, Javier|||0000-0003-3288-3496
  • Falcón-Pérez, Juan M.|||0000-0003-3133-0670
  • Barrio, Rosa|||0000-0002-9663-0669
  • Macarulla Mercadé, Teresa|||0000-0002-5856-4082
  • Mato, José M.
  • Martínez Chantar, Maria L.
  • Cordon Cardo, Carlos
  • Aransay, Ana M.|||0000-0002-8271-612X
  • Marks, Kevin
  • Baselga Torres, Josep
  • Tabernero, Josep|||0000-0002-2495-8139
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Manning, Brendan D.
  • Marjon, Katya
  • Carracedo, Arkaitz|||0000-0001-5957-1260
Activation of the PTEN-PI3K-mTORC1 pathway consolidates metabolic programs that sustain cancer cell growth and proliferation,. Here we show that mTORC1 regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. Through the use of integrative metabolomics in a mouse model and human biopsies of prostate cancer, we identified alterations in tumours impacting on the production of decarboxylated S-adenosylmethionine (dcSAM) and polyamine synthesis. Mechanistically, this metabolic rewiring stems from mTORC1-dependent regulation of S-adenosylmethionine decarboxylase 1 (AMD1) stability. This novel molecular regulation was validated in murine and human cancer specimens. AMD1 was upregulated in prostate cancer specimens with activated mTORC1. Conversely, samples from a clinical trial with the mTORC1 inhibitor everolimus exhibited a predominant decrease in AMD1 immunoreactivity that was associated to a decrease in proliferation, in line with the requirement of dcSAM production for oncogenicity. These findings provide fundamental information about the complex regulatory landscape controlled by mTORC1 to integrate and translate growth signals into an oncogenic metabolic program.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer

  • Hermanova, Ivana
  • Zúñiga-García, Patricia
  • Caro-Maldonado, Alfredo|||0000-0002-5431-7949
  • Fernandez-Ruiz, Sonia
  • Salvador Velez, Fernando Maria|||0000-0002-0546-1354
  • Martín-Martín, Natalia|||0000-0002-2527-429X
  • Zabala-Letona, Amaia
  • Nuñez-Olle, Marc|||0000-0002-3593-2591
  • Torrano, Verónica
  • Camacho, Laura
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
  • Talamillo, Ana
  • Carreira, Suzanne|||0000-0002-5077-5379
  • Gurel, Bora|||0000-0002-5018-8078
  • Cortazar, Ana Rosa|||0000-0002-7082-5695
  • Guiu, Marc|||0000-0002-7083-986X
  • López, Jose I.|||0000-0003-0842-5348
  • Martinez-Romero, Anabel
  • Astobiza, Ianire|||0000-0002-7142-7066
  • Valcarcel, Lorea|||0000-0002-7309-9924
  • Lorente, Mar|||0000-0003-0982-0956
  • Arruabarrena-Aristorena, Amaia|||0000-0002-1636-3944
  • Velasco, Guillermo|||0000-0002-1994-2386
  • Gomez Muñoz, Antonio|||0000-0002-2539-016X
  • Suárez-Cabrera, Cristian|||0000-0003-1897-1596
  • Lodewijk, Iris
  • Flores, Juana M.|||0000-0002-7995-4426
  • Sutherland, James D.|||0000-0003-3229-793X
  • Barrio, Rosa|||0000-0002-9663-0669
  • de Bono, Johann S.|||0000-0002-2034-595X
  • Paramio, Jesús M.|||0000-0001-7520-3177
  • Trka, Jan|||0000-0002-9527-8608
  • Graupera, Mariona|||0000-0003-4608-4185
  • Gomis, Roger R.|||0000-0001-6473-2858
  • Carracedo, Arkaitz|||0000-0001-5957-1260
This study unravels an unprecedented murine model of lethal metastatic prostate cancer, based on the combined deletion of Pten and Lkb1. Importantly, minimal activity of LKB1 is sufficient to hamper prostate cancer cell aggressiveness, thus redefining the relationship between gene dosage and tumor suppression. Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model an aggressive form of prostate cancer and show the unconventional association of LKB1 dosage to prostate tumorigenesis. Whereas loss of Lkb1 alone in the murine prostate epithelium was inconsequential for tumorigenesis, its combination with an oncogenic insult, illustrated by Pten heterozygosity, elicited lethal metastatic prostate cancer. Despite the low frequency of LKB1 deletion in patients, this event was significantly enriched in lung metastasis. Modeling the role of LKB1 in cellular systems revealed that the residual activity retained in a reported kinase-dead form, LKB1 K78I, was sufficient to hamper tumor aggressiveness and metastatic dissemination. Our data suggest that prostate cells can function normally with low activity of LKB1, whereas its complete absence influences prostate cancer pathogenesis and dissemination.